Vigil Neuroscience, Inc. (VIGL)
Largest Insider Buys in Sector
VIGL Stock Price History Chart
VIGL Stock Performance
About Vigil Neuroscience, Inc.
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral …
Insider Activity of Vigil Neuroscience, Inc.
Over the last 12 months, insiders at Vigil Neuroscience, Inc. have bought $0 and sold $0 worth of Vigil Neuroscience, Inc. stock.
On average, over the past 5 years, insiders at Vigil Neuroscience, Inc. have bought $35.35M and sold $4,200 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 4,000 shares for transaction amount of $15,000 was made by Magovcevic-Liebisch Ivana (President and CEO) on 2023‑11‑20.
List of Insider Buy and Sell Transactions, Vigil Neuroscience, Inc.
| 2023-11-20 | President and CEO | 4,000 0.0114% | $3.75 | $15,000 | -7.90% | |||
| 2022-11-18 | Sale | Chief Medical Officer | 300 0.001% | $14.00 | $4,200 | -27.38% | ||
| 2022-05-16 | 14,893 0.0551% | $2.97 | $44,189 | +235.79% | ||||
| 2022-05-05 | SVP, Head of Early Development | 1,500 0.0064% | $4.00 | $6,000 | +185.03% | |||
| 2022-05-03 | Chief Financial Officer | 4,000 0.0149% | $3.77 | $15,098 | +163.16% | |||
| 2022-05-03 | General Counsel | 4,000 0.0148% | $3.77 | $15,074 | +163.16% | |||
| 2022-05-03 | Chief Medical Officer | 4,000 0.0134% | $3.40 | $13,591 | +163.16% | |||
| 2022-05-02 | President and CEO | 4,000 0.0141% | $3.61 | $14,439 | +160.99% | |||
| 2022-03-28 | 3,000 0.0114% | $7.20 | $21,604 | +25.92% | ||||
| 2022-01-11 | director | 1.68M 7.4164% | $14.00 | $23.45M | -24.96% | |||
| 2022-01-11 | 10 percent owner | 1.68M 7.4164% | $14.00 | $23.45M | -24.96% | |||
| 2022-01-11 | director | 535,000 2.3688% | $14.00 | $7.49M | -24.96% | |||
| 2022-01-11 | 10 percent owner | 535,000 2.3688% | $14.00 | $7.49M | -24.96% | |||
| 2022-01-11 | director | 265,000 1.1733% | $14.00 | $3.71M | -24.96% | |||
| 2022-01-11 | 10 percent owner | 355,000 1.5718% | $14.00 | $4.97M | -24.96% |
Insider Historical Profitability
| Vitorovic Stefan | director | 5004393 12.2418% | $2.98 | 1 | 0 | <0.0001% |
| Vida Ventures GP III, L.L.C. | 10 percent owner | 5004393 12.2418% | $2.98 | 1 | 0 | <0.0001% |
| Booth Bruce | director | 4808896 11.7636% | $2.98 | 1 | 0 | <0.0001% |
| Atlas Venture Fund XII, L.P. | 10 percent owner | 4808896 11.7636% | $2.98 | 1 | 0 | <0.0001% |
| Thorp Clay | 1556030 3.8064% | $2.98 | 3 | 0 | +78.92% |
Institutional Investor Ownership
| Atlas Venture Life Science Advisors Llc | $19.9M | 15.53 | 5.84M | 0% | +$0 | 1.85 | |
| Northpond Partners LLC | $14.37M | 11.21 | 4.21M | 0% | +$0 | 0.32 | |
| Citadel Advisors LLC | $7.39M | 5.76 | 2.17M | +0.18% | +$13,329.69 | <0.01 | |
| Bvf Inc Il | $6.18M | 4.83 | 1.81M | 0% | +$0 | 0.05 | |
| Artal Group S A | $6.18M | 4.82 | 1.81M | 0% | +$0 | 0.03 |